On Nov 01, major Wall Street analysts update their ratings for $Penumbra (PEN.US)$, with price targets ranging from $232 to $248.
Deutsche Bank analyst Pito Chickering maintains with a buy rating, and adjusts the target price from $205 to $241.
Baird analyst David Rescott maintains with a buy rating, and adjusts the target price from $180 to $248.
Needham analyst Michael Matson maintains with a hold rating.
Stifel analyst Mathew Blackman maintains with a buy rating, and maintains the target price at $238.
BTIG analyst Ryan Zimmerman maintains with a buy rating, and adjusts the target price from $234 to $232.
Furthermore, according to the comprehensive report, the opinions of $Penumbra (PEN.US)$'s main analysts recently are as follows:
The company's Q3 earnings surpassed expectations. Enrollment for the THUNDER trial concluded in Q3, and the firm achieved FDA clearance for two new CAVT products, Lightning Bolt 6X and 12. Looking forward, it is anticipated that innovation in a highly under-penetrated market will propel the company's double-digit revenue growth and contribute to significant margin expansion.
The firm's assessment indicates that the third quarter revenue and operating margin exceed expectations, reinforcing belief in the company's ability to meet its revised full-year guidance and in the anticipated growth acceleration for the following year, which is seen as essential for the stock's upward trajectory.
Here are the latest investment ratings and price targets for $Penumbra (PEN.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月1日，多家华尔街大行更新了$Penumbra (PEN.US)$的评级，目标价介于232美元至248美元。
德意志银行分析师Pito Chickering维持买入评级，并将目标价从205美元上调至241美元。
贝雅分析师David Rescott维持买入评级，并将目标价从180美元上调至248美元。
Needham分析师Michael Matson维持持有评级。
斯迪富分析师Mathew Blackman维持买入评级，维持目标价238美元。
BTIG分析师Ryan Zimmerman维持买入评级，并将目标价从234美元下调至232美元。
此外，综合报道，$Penumbra (PEN.US)$近期主要分析师观点如下：
公司的第三季度收入超出预期。 THUNDER 试验的招生已在第三季度结束，该公司为两款新产品 CAVt Lightning Bolt 6X 和 12 获得了 FDA 批准。展望未来，预计在一个需求濒临饱和的市场中的创新将推动公司的两位数营业收入增长，并有助于显著拓展利润率。
公司的评估表明，第三季度营业收入和营业利润率超出预期，强化了对公司能够实现修订后全年指引并预期下一年增速的信心，这被视为对股票上升轨迹至关重要。
以下为今日7位分析师对$Penumbra (PEN.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
